The second consecutive guidance raise and record EBITDA underscore strong LINZESS momentum driven by improved net price and mid-single-digit demand growth. Monitor the STARS-2 apraglutide trial for regulatory filing plans in 2029 and any acceleration opportunities. The CEO transition is orderly and non-disruptive.
Drug in focus
Linzess
● Neutral Named in this 8-K- Impact
- Phase
- Approved / marketed (Phase 3 completed for the pediatric ages 2–5 sNDA)
- Time to market
- Already marketed in the U.S. since FDA approval in 2012; the only pending item was the pediatric (ages 2–5) label-expansion sNDA decided around its May 24, 2026 PDUFA date.
- Next catalyst
- None dated
What to watchFor ABBV holders, Linzess is immaterial to the thesis, treat it as steady, profitable co-marketed revenue, not a catalyst. Watch the 2026-08-06 IRWD Q2 earnings print (the co-commercialization partner) for Linzess U.S. net-sales momentum and any update on the ages 2–5 pediatric label decision from the May 2026 PDUFA, which the local data does not yet record as approved or rejected.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $4.03entry
- T+1 · 11d ago +8.93%α +8.62% · $4.39
- T+5 · 5d ago +20.35%α +17.06% · $4.85
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ironwood Pharmaceuticals reported Q3 2026 total revenue of $133.0M (up 9.0% YoY from $122.1M) and GAAP EPS of $0.36 (up from $0.23), beating consensus estimates of $121.6M and $0.31. The company raised full-year 2026 guidance for the second consecutive quarter: LINZESS U.S. net sales to $1.20-$1.25B, total revenue to $485-$510M, and adjusted EBITDA to >$350M. LINZESS U.S. net sales reached $324.9M in Q3, with year-to-date sales of $880M already exceeding full-year 2025.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $133.0M vs $122.1M YoY, beating consensus of $121.6M
- GAAP EPS $0.36 vs $0.23 YoY, beating consensus of $0.31
- Full-year 2026 guidance raised: LINZESS net sales to $1.20-$1.25B, total revenue to $485-$510M, adjusted EBITDA >$350M
- LINZESS U.S. net sales $324.9M in Q3, up 3.2% YoY; YTD $880M exceeds full-year 2025 total
- Adjusted EBITDA of $97.9M, a record, vs $81.8M in Q3 2025
- Operating cash flow $130.8M in Q3 vs $47.6M in Q3 2025
- Revolving credit facility reduced by $60M to $325.0M outstanding
- CEO transition announced: Tammi Gaskins to become CEO effective Jan 1, 2027; Tom McCourt to retire
Financial Impact
Revenue beat of ~$11.4M (9.4%) vs consensus; EPS beat of $0.05 (16.1%); guidance raised by $25M at midpoint for revenue and $40M for adjusted EBITDA
Risk Factors
- LINZESS faces potential generic competition and patent challenges
- Apraglutide STARS-2 trial results are uncertain and regulatory approval not guaranteed
- High debt load of $325M on revolving credit facility despite reduction
- Revenue concentration on single product LINZESS through AbbVie collaboration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-123029 |
| Document: tm2629044d1_8k.htm | 0001104659-26-123029 |
| Document: 0001104659-26-123029-index-headers.html | 0001104659-26-123029 |
| Document: 0001104659-26-123029-index.html | 0001104659-26-123029 |
| Document: 0001104659-26-123029.txt | 0001104659-26-123029 |
| 8-K Data (Synthetic) | 0001104659-26-123029 |
Track record
13 reports on IRWD
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +12.27% at T+20 after the Feb 23, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.88 Now $4.85 −0.51% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $4.84 Now $4.85 +0.21% settles Dec 15
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.81 Now $4.85 +0.83% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $4.81 Now $4.85 +0.83% settles Dec 9
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $4.03 Now $4.85 +20.35% settles Dec 4
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $3.61 Now $4.85 +34.35% settles Nov 25
- Oct 16, 20264w ago 8-K Neutral 3/10 Entry $3.50 to $4.85 Now $4.85 +38.57% ▲ +38.57% +39.73% vs SPY
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $4.26 to $4.29 Now $4.85 +13.85% ▲ +0.70% +0.10% vs SPY
- May 13, 202626w ago 8-K Mixed 6/10 Entry $3.68 to $3.63 Now $4.85 +31.79% ▼ −1.36% −0.75% vs SPY
- May 7, 202627w ago 8-K Bullish 7/10 Entry $4.17 to $3.24 Now $4.85 +16.31% ▼ −22.30% −25.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers